Class information for:
Level 1: TOFACITINIB//JAK3//JANUS KINASE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
13676 820 43.9 89%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
422 3       C REACTIVE PROTEIN//STAT3//HAPTOGLOBIN 28303
1051 2             STAT3//GP130//ONCOSTATIN M 10071
13676 1                   TOFACITINIB//JAK3//JANUS KINASE 820

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 TOFACITINIB authKW 1231548 8% 53% 63
2 JAK3 authKW 1002055 7% 46% 58
3 JANUS KINASE authKW 546235 8% 24% 62
4 JANUS KINASE INHIBITOR authKW 393941 3% 46% 23
5 JAK3 INHIBITOR authKW 364912 2% 70% 14
6 CP 690 550 authKW 357469 1% 80% 12
7 JAK1 INHIBITOR authKW 301616 1% 90% 9
8 BARICITINIB authKW 297894 1% 100% 8
9 TYK2 authKW 264834 3% 34% 21
10 MOL IMMUNOL INFLAMMAT BRANCH address 212254 4% 17% 33

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Rheumatology 2944 11% 0% 91
2 Chemistry, Medicinal 2170 16% 0% 129
3 Immunology 1360 21% 0% 170
4 Biochemistry & Molecular Biology 402 22% 0% 180
5 Pharmacology & Pharmacy 317 14% 0% 113
6 Transplantation 288 4% 0% 35
7 Hematology 287 6% 0% 53
8 Cell Biology 246 11% 0% 88
9 Chemistry, Organic 209 9% 0% 72
10 Biophysics 72 5% 0% 37

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MOL IMMUNOL INFLAMMAT BRANCH 212254 4% 17% 33
2 TRANSLAT IMMUNOL SECT 121633 1% 47% 7
3 ANTIBACTERIALS IMMUNOL 111710 0% 100% 3
4 PARKER HUGHES CANC 107224 1% 24% 12
5 EXPT BMT PROGRAM 83781 0% 75% 3
6 CNRS UMR 9942 74474 0% 100% 2
7 INFLAMMAT PULM DIS TEAM 74474 0% 100% 2
8 IRMA LERMA RANGEL ILR PHARM 74474 0% 100% 2
9 PEDIAT RHEUMATOL BRANCH 74474 0% 100% 2
10 CARDIOTHORAC SURGTRANSPLANTAT IMMUNOL 67024 0% 60% 3

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT 7751 1% 3% 7
2 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 3351 6% 0% 48
3 ARTHRITIS & RHEUMATOLOGY 1809 1% 1% 7
4 EXPERT OPINION ON THERAPEUTIC PATENTS 1657 1% 0% 10
5 ANNALS OF THE RHEUMATIC DISEASES 1647 2% 0% 20
6 ARTHRITIS RESEARCH & THERAPY 1363 1% 0% 11
7 JOURNAL OF IMMUNOLOGY 1171 5% 0% 42
8 EXPERT REVIEW OF CLINICAL IMMUNOLOGY 1165 1% 1% 5
9 JOURNAL OF MEDICINAL CHEMISTRY 963 3% 0% 24
10 BLOOD 749 3% 0% 27

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 TOFACITINIB 1231548 8% 53% 63 Search TOFACITINIB Search TOFACITINIB
2 JAK3 1002055 7% 46% 58 Search JAK3 Search JAK3
3 JANUS KINASE 546235 8% 24% 62 Search JANUS+KINASE Search JANUS+KINASE
4 JANUS KINASE INHIBITOR 393941 3% 46% 23 Search JANUS+KINASE+INHIBITOR Search JANUS+KINASE+INHIBITOR
5 JAK3 INHIBITOR 364912 2% 70% 14 Search JAK3+INHIBITOR Search JAK3+INHIBITOR
6 CP 690 550 357469 1% 80% 12 Search CP+690+550 Search CP+690+550
7 JAK1 INHIBITOR 301616 1% 90% 9 Search JAK1+INHIBITOR Search JAK1+INHIBITOR
8 BARICITINIB 297894 1% 100% 8 Search BARICITINIB Search BARICITINIB
9 TYK2 264834 3% 34% 21 Search TYK2 Search TYK2
10 JAK1 194791 2% 28% 19 Search JAK1 Search JAK1

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 CLARK, JD , FLANAGAN, ME , TELLIEZ, JB , (2014) DISCOVERY AND DEVELOPMENT OF JANUS KINASE (JAK) INHIBITORS FOR INFLAMMATORY DISEASES.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 57. ISSUE 12. P. 5023 -5038 45 64% 45
2 GHORESCHI, K , LAURENCE, A , O'SHEA, JJ , (2009) JANUS KINASES IN IMMUNE CELL SIGNALING.IMMUNOLOGICAL REVIEWS. VOL. 228. ISSUE . P. 273 -287 54 39% 330
3 NAKAYAMADA, S , KUBO, S , IWATA, S , TANAKA, Y , (2016) CHEMICAL JAK INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 17. ISSUE 16. P. 2215 -2225 44 70% 0
4 VIJAYAKRISHNAN, L , VENKATARAMANAN, R , GULATI, P , (2011) TREATING INFLAMMATION WITH THE JANUS KINASE INHIBITOR CP-690,550.TRENDS IN PHARMACOLOGICAL SCIENCES. VOL. 32. ISSUE 1. P. 25 -34 39 70% 43
5 IWATA, S , TANAKA, Y , (2016) PROGRESS IN UNDERSTANDING THE SAFETY AND EFFICACY OF JANUS KINASE INHIBITORS FOR TREATMENT OF RHEUMATOID ARTHRITIS.EXPERT REVIEW OF CLINICAL IMMUNOLOGY. VOL. 12. ISSUE 10. P. 1047 -1057 36 73% 0
6 HAAN, C , ROLVERING, C , RAULF, F , KAPP, M , DRUCKES, P , THOMA, G , BEHRMANN, I , ZERWES, HG , (2011) JAK1 HAS A DOMINANT ROLE OVER JAK3 IN SIGNAL TRANSDUCTION THROUGH GAMMA C-CONTAINING CYTOKINE RECEPTORS.CHEMISTRY & BIOLOGY. VOL. 18. ISSUE 3. P. 314-323 36 64% 76
7 DYMOCK, BW , YANG, EG , CHU-FARSEEVA, Y , YAO, LB , (2014) SELECTIVE JAK INHIBITORS.FUTURE MEDICINAL CHEMISTRY. VOL. 6. ISSUE 12. P. 1439 -1471 47 52% 9
8 MENET, CJ , MAMMOLITI, O , LOPEZ-RAMOS, M , (2015) PROGRESS TOWARD JAK1-SELECTIVE INHIBITORS.FUTURE MEDICINAL CHEMISTRY. VOL. 7. ISSUE 2. P. 203 -235 31 79% 1
9 FLANAGAN, ME , BLUMENKOPF, TA , BRISSETTE, WH , BROWN, MF , CASAVANT, JM , SHANG-POA, C , DOTY, JL , ELLIOTT, EA , FISHER, MB , HINES, M , ET AL (2010) DISCOVERY OF CP-690,550: A POTENT AND SELECTIVE JANUS KINASE (JAK) INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND ORGAN TRANSPLANT REJECTION.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 53. ISSUE 24. P. 8468 -8484 27 79% 107
10 ARCHER, TP , MORAN, GW , GHOSH, S , (2016) TOFACITINIB IN ULCERATIVE COLITIS.IMMUNOTHERAPY. VOL. 8. ISSUE 5. P. 495 -502 34 71% 0

Classes with closest relation at Level 1


Rank Class id link
1 3696 STAT1//STAT5//STAT
2 12297 SEVERE COMBINED IMMUNODEFICIENCY//OMENN SYNDROME//PRIMARY IMMUNODEFICIENCY
3 18972 SYK//SPLEEN TYROSINE KINASE//FOSTAMATINIB
4 115 ESSENTIAL THROMBOCYTHEMIA//POLYCYTHEMIA VERA//MYELOFIBROSIS
5 7823 INTERLEUKIN 7//IL 7//INTERLEUKIN 7 RECEPTOR
6 7798 SOCS1//SOCS//SOCS3
7 13382 INTERFERON RECEPTOR//IFNAR1//IFNAR2
8 1141 RHEUMATOID ARTHRITIS//ABATACEPT//TOCILIZUMAB
9 5366 STAT3//GRIM 19//STAT3 INHIBITOR
10 21958 IL 9//INTERLEUKIN 9//TH9 CELLS

Go to start page